Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Supercharged immune cells take on nasopharyngeal cancer

NCT ID NCT02065362

First seen Jan 31, 2026 · Last updated May 20, 2026 · Updated 11 times

Summary

This early-stage study tests a new immune cell therapy for people with a type of throat cancer linked to the Epstein-Barr virus. Researchers take the patient's own T cells, train them to recognize the virus on cancer cells, and add a gene to make them resist a chemical that tumors use to hide. The goal is to see if these enhanced cells are safe and can survive in the body to fight the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV-POSITIVE NASOPHARYNGEAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.